Recent Research Analysts’ Ratings Changes for Personalis (PSNL)

Several brokerages have updated their recommendations and price targets on shares of Personalis (NASDAQ: PSNL) in the last few weeks:

• 3/8/2026 – Personalis was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/5/2026 – Personalis had its price target lowered by Morgan Stanley from $11.00 to $10.00. They now have an “equal weight” rating on the stock.
• 2/28/2026 – Personalis was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/27/2026 – Personalis had its price target raised by Needham & Company LLC from $10.00 to $12.00. They now have a “buy” rating on the stock.
• 2/11/2026 – Personalis had its price target raised by BTIG Research from $12.00 to $13.00. They now have a “buy” rating on the stock.
• 1/31/2026 – Personalis was upgraded by Wall Street Zen from “sell” to “hold”.
• 1/26/2026 – Personalis had its price target raised by Guggenheim from $12.00 to $13.00. They now have a “buy” rating on the stock.
• 1/22/2026 – Personalis had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/9/2026 – Personalis had its “buy” rating reaffirmed by BTIG Research. They now have a $12.00 price target on the stock.

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.